Projections onto the Pareto surface in multicriteria radiation therapy optimization
Rasmus Bokrantz and Kaisa Miettinen

Citation: Medical Physics 42, 5862 (2015); doi: 10.1118/1.4930252
View online: http://dx.doi.org/10.1118/1.4930252
View Table of Contents: http://scitation.aip.org/content/aapm/journal/medphys/42/10?ver=pdfcov
Published by the American Association of Physicists in Medicine

Articles you may be interested in
Multicriteria optimization of the spatial dose distribution
Med. Phys. 40, 121720 (2013); 10.1118/1.4828840

Simultaneous navigation of multiple Pareto surfaces, with an application to multicriteria IMRT planning with multiple beam angle configurations
Med. Phys. 37, 736 (2010); 10.1118/1.3292636

A toolbox for intensity modulated radiation therapy optimization
Med. Phys. 30, 2320 (2003); 10.1118/1.1598171

Beyond bixels: Generalizing the optimization parameters for intensity modulated radiation therapy
Med. Phys. 29, 2298 (2002); 10.1118/1.1508799

Determination and use of radiobiological response parameters in radiation therapy optimization (in English)
Med. Phys. 29, 1639 (2002); 10.1118/1.1489047
Projections onto the Pareto surface in multicriteria radiation therapy optimization

Rasmus Bokrantz1,2
Optimization and Systems Theory, Department of Mathematics, KTH Royal Institute of Technology, Stockholm SE-100 44, Sweden and RaySearch Laboratories, Sveavägen 44, Stockholm SE-103 65, Sweden

Kaisa Miettinen
Optimization and Systems Theory, Department of Mathematics, KTH Royal Institute of Technology, SE-100 44 Stockholm, Sweden and University of Jyvaskyla, Department of Mathematical Information Technology, FI-400 14 University of Jyvaskyla, Finland

(Received 10 September 2014; revised 25 August 2015; accepted for publication 26 August 2015; published 16 September 2015; corrected 28 September 2015)

Purpose: To eliminate or reduce the error to Pareto optimality that arises in Pareto surface navigation when the Pareto surface is approximated by a small number of plans.

Methods: The authors propose to project the navigated plan onto the Pareto surface as a postprocessing step to the navigation. The projection attempts to find a Pareto optimal plan that is at least as good as or better than the initial navigated plan with respect to all objective functions. An augmented form of projection is also suggested where dose–volume histogram constraints are used to prevent the projection causes a violation of some clinical goal. The projections were evaluated with respect to planning for intensity modulated radiation therapy delivered by step-and-shoot and sliding window and spot-scanned intensity modulated proton therapy. Retrospective plans were generated for a prostate and a head and neck case.

Results: The projections led to improved dose conformity and better sparing of organs at risk (OARs) for all three delivery techniques and both patient cases. The mean dose to OARs decreased by 3.1 Gy on average for the unconstrained form of the projection and by 2.0 Gy on average when dose–volume histogram constraints were used. No consistent improvements in target homogeneity were observed.

Conclusions: There are situations when Pareto navigation leaves room for improvement in OAR sparing and dose conformity, for example, if the approximation of the Pareto surface is coarse or the problem formulation has too permissive constraints. A projection onto the Pareto surface can identify an inaccurate Pareto surface representation and, if necessary, improve the quality of the navigated plan. © 2015 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4930252]

Key words: multicriteria, Pareto optimality, projection, radiation therapy, optimization

1. INTRODUCTION

Radiation therapy treatment planning is generally guided toward fulfillment of a set of physician-defined plan evaluation criteria. These criteria are sometimes incompatible, and the treatment planner is therefore asked to find a suitable trade-off between the conflicting ones. The main tools that planners then have at their disposal are weights associated with the objective functions that drive the treatment plan optimization. These weights often need extensive tuning before the optimized plan meets approval, which can be time-consuming. Inefficient plan preparation is undesirable because it can cause a time lag between diagnosis and the first treatment fraction and poses a risk that plan quality is compromised in the interest of time.

Pareto surface navigation is an alternative planning technique that has recently entered clinical use, see, e.g., Craft and references therein. This technique avoids a priori prioritization of the objectives. A representation of all the possible trade-offs between the objectives is instead calculated, which the planner or physician can explore through linear interpolation of the precalculated plans’ doses. Studies indicate that this form of navigation generally permits an acceptable plan to be identified within a time frame of tens of minutes or less. The mathematical basis for Pareto surface navigation is multicriteria optimization, meaning optimization with multiple objectives where any feasible solution such that no objective can be improved without deteriorating at least one of the others is considered optimal (Pareto optimal), see, e.g., Miettinen. Nevertheless, Craft and Bortfeld both observed approximation errors above 10% for representations with less than about 20 plans, and that up to about 75 plans are needed to reduce the error below 5%. These studies considered between five to ten objectives.
In view of these concerns, we present a technique that eliminates or reduces the error to Pareto optimality through the minimization of a projective distance between the navigated plan and the Pareto surface. We use a formulation of this projection as in Nakayama, which attempts to find a plan that is at least as good as or better than the navigated plan with respect to all objectives. We also suggest an augmented formulation where constraints are imposed on maintained dose–volume histogram (DVH) quality. We quantify the dosimetric benefit as in Nakayama, where constraints are imposed on maintained dose–volume inequality for at least one index. This formulation is a variant of an achievement perspective, therefore, entails to select the single, best preferred, Pareto optimal plan with at least as good or better performance in all objectives. Specifically, we propose to solve the following optimization problem as a postprocessing step to the navigation:

\[
\begin{align*}
\text{minimize} & \quad \max_{i=1,...,n} \left\{ \frac{f_i(x) - f_i(\bar{x})}{f_i(\bar{x}) - z_i^*} \right\} \\
\text{subject to} & \quad x \in \mathcal{X},
\end{align*}
\]

where \(z_i^*\) is the ideal point, i.e., \(z_i^* = \min_{j=1,...,m} f_j(x_j)\) for \(i = 1,...,n\). This formulation is a variant of an achievement function suggested by Wierzbicki, which projects the navigated point \(f(x)\) along a ray toward the ideal objective function vector \(z^*\), see Fig. 2. The particular achievement function that is used in Eq. (2) has been used previously by Nakayama, Buchanan and Gardiner observed that decision makers tend to prefer this form of minimization of the distance to the ideal point over maximization of the distance from the worst feasible point if the reference point is attainable, as is the case for \(f(\bar{x})\).
The navigated plan $\bar{x}$ is a feasible solution to Eq. (2) with an objective value of zero. An optimal solution $x^*$ to Eq. (2) therefore satisfies $f_i(x^*) \leq f_i(\bar{x})$ for $i = 1, \ldots, n$, meaning that $x^*$ is at least as good as or better than the navigated plan with respect to all objectives. Further, $x^*$ is weakly Pareto optimal because the achievement function in Eq. (2) is strictly increasing (Ref. 6, Theorem 3.5.4). If solutions that are weakly Pareto optimal but not Pareto optimal are to be avoided, it is possible to augment the objective function of Eq. (2) with the term $\rho \sum_{i=1}^{n} f_i(x)/(f_i(x) - z_i^*)$ for some sufficiently small positive scalar $\rho$, as discussed in Miettinen (Ref. 6, Section 5.8). Addition of this term makes the objective function strongly increasing, which ensures Pareto optimality (Ref. 6, Theorem 3.5.4). With regard to numerical stability, observe that the denominator in Eq. (2) can approach zero if the navigated point $f(\bar{x})$ becomes very close to the ideal point $z^*$ in some component. The ideal point should therefore for numerical purposes be replaced with an utopian objective vector that is better by some small but numerically significant positive value (Ref. 6, Definition 2.4.2).

2.C. Dose–volume histogram constraints

A commonly used formulation for radiation therapy optimization is penalization of the deviation from the desired dose to each anatomical structure, see, e.g., Oelfke and Bortfeld. Objectives functions of this type cannot capture all aspects of plan quality, for instance, they do not take the 3D shape of the dose into account nor the biological effect of the irradiation. It is, therefore, possible for a clinician to judge a plan obtained from formulation (1) as worse than the initial navigated plan even though it is better as measured by all objectives $f_1, \ldots, f_n$.

To mitigate any deterioration in plan quality not captured by the objectives, we consider an augmented version of formulation (2) that prevents deterioration with respect to clinical goals. We restrict ourselves to consider clinical goals that are related to the DVH distribution of the navigated plan. Consequently, we introduce constraints that require each DVH curve of the projected plan to lie between the corresponding DVH curve for the navigated plan and a vertical line that intersects the dose axis at the prescription level for targets and at zero for organs at risk (OARs), see Fig. 3. These requirements ensure that a DVH criterion that is satisfied by the navigated plan cannot become violated after the projection.

The DVH requirements are implemented using functions that impose a one-sided penalty on the error between the DVH curves associated with the current dose $d$ and the navigated dose $\bar{d}$. The one-sidedness prevents penalization of when $d$ has better normal tissue sparing or target coverage than $\bar{d}$. To define the DVH functions mathematically, let $D(\cdot; d)$ be the function that parametrizes the DVH curve for some subvolume $V$ along the cumulative volume axis, i.e.,

$$D(v; d) = \max \left\{ d' \in \mathbb{R} : \left| q \in V : d(q) \geq d' \right| V \right\} \geq v,$$

where $v$ denotes cumulative volume in percent, $d(q)$ is the dose to some point $q \in V$, and $|V|$ is the volume of $V$. In other words, $D(v; d)$ is the DVH point associated with some dose $d$ and cumulative volume $v$. Let also $\hat{d}$ denote the prescription level for targets and zero for OARs, $\hat{v}$ denote the cumulative volume such that $\hat{d} = D(\hat{v}, \hat{d})$, and $(\cdot)_+$ denote the positive part operator $\max\{\cdot, 0\}$. Then, a min reference DVH constraint takes the form

$$\int_{\hat{v}}^{1} (D(v; d) - D(v; \hat{d}))_+ \, dv \leq 0,$$

while a max reference DVH constraint takes the form

$$\int_{0}^{\hat{v}} (D(v; d) - D(v; \hat{d}))_+ \, dv \leq 0.$$
The requirements in Fig. 3 are implemented by assignment of a max reference DVH constraint to each OAR, and assignment of a min reference DVH and max reference DVH constraint to each target. Similar reference DVH functions have been used previously in the work of Bokrantz and Fredriksson.

The use of DVH constraints leads to a nonconvex optimization formulation. An optimization solver can therefore not guarantee more than convergence to a locally optimal point. Some studies have, however, shown that the nonconvexity of DVH functions does not lead to severe local optimality effects in practice, possibly because the nonconvexities disappear or become negligible due to the physical properties of radiation delivery. Regardless of convergence, the introduction of additional constraints implies that the projected solution, in general, lies in the interior of the feasible objective space and not on the Pareto surface itself.

2.D. Computational study

The projections were evaluated with respect to three delivery techniques: ss-IMRT, sw-IMRT, and IMPT and two tumor sites: prostate and head and neck. We first outline our numerical implementation, then describe the studied patient cases and delivery techniques, and finally summarize our set of evaluation criteria.

2.D.1. Numerical optimization

The projections were implemented as an add-on to the multicriteria optimization module in RayStation v2.4 (RaySearch Laboratories, Stockholm, Sweden). This treatment planning system’s optimization solver (a quasi-Newton sequential quadratic programming method) requires a continuously differentiable objective and constraints. The nondifferentiability of the maximum in Eq. (2) was handled by the addition of a term, with being a positive infinitesimal value, to the arguments of the maximization so that they become positive, see also Nakayama (Ref. 25, Remark 3.1), followed by a substitution of a smooth power mean function for the maximum operator according to

\[
\text{max}_{i=1,\ldots,n} x_i \approx \left( \frac{1}{n} \sum_{i=1}^{n} x_i^p \right)^{1/p}.
\]

This approximation approaches the exact maximum of some positive \(x_1,\ldots,x_n\) as \(p \to \infty\). A parameter value of \(p = 10\) was used for all numerical experiments in this paper, guided by the close relationship between Eq. (3) and an equivalent uniform dose (EUD) functions (the EUD is the power mean of the dose, with the power \(p\) determined by the EUD parameter \(a\), cf. Niemierko). An EUD function with an EUD parameter of about 10 is common for serial organs such as the spinal cord where the risk for complication highly depends on the maximum dose value, see, e.g., Thieke et al.

Approximation (3) means that the results in Sec. 2.B do not hold rigorously for our numerical implementation. In particular, it is possible that the projection can lead to a mild degradation in objective function value compared to the navigated point for some objectives. Nevertheless, formulation (3) amounts to minimization of a strongly increasing achievement function, and it therefore finds Pareto optimal points (Ref. 6, Theorem 3.5.4). If it is critical to maintain objective function values exactly, then an everywhere differentiable epigraph reformulation of Eq. (2) according to

\[
\begin{align*}
\text{minimize} & \quad t \\
\text{subject to} & \quad f_i(x) - f_i(\bar{x}) \leq t, & i = 1,\ldots,n, \\
& \quad x \in \mathcal{X},
\end{align*}
\]

could be preferable to Eq. (3). The auxiliary nonlinear constraints of this formulation, however, make it more computationally expensive to solve than formulation (2) combined with approximation (3).

2.E. Patient data and machine model

Retrospective planning was performed with respect to the following two patient cases:

- A prostate cancer patient with a prescribed dose of 59.2 Gy to the prostate and seminal vesicles, with a simultaneous boost of 74 Gy to the prostate. Considered critical structures were the bladder and rectum.
- A head and neck cancer patient with a prescribed dose of 66, 60, and 50 Gy to the primary target, high risk nodal regions, and low risk nodal regions, respectively. Considered critical structures were the brainstem, parotid glands, and spinal cord.

Treatment planning for IMRT was performed with respect to a Varian 2100 linear accelerator (Varian Medical Systems, Palo Alto, California), with ten static segments per field for ss-IMRT and 320 dynamic control points per field for sw-IMRT. A coplanar five-field setup was used for the prostate case and a coplanar seven-field setup used for the head and neck case. Planning for IMPT was for the prostate case performed with respect to two coplanar and parallel-opposed fields and for the head and neck case performed with respect to two coplanar fields with a perpendicular setup. A dose grid resolution of \(3 \times 3 \times 3 \text{ mm}^3\) was used for all calculations. The optimizations were performed with respect to least-squares penalties on the deviation in voxel dose or EUD from a scalar-valued reference level, see the Appendix for a complete list functions and Bokrantz (Ref. 19, Appendix C) for mathematical definitions.

2.F. Treatment plan generation

A total of \(2n\) Pareto optimal plans was generated per delivery technique and patient case. RayStation uses the algorithm in the work of Bokrantz and Forsgren for this calculation. A single plan was then selected by Pareto surface navigation, and the projection finally applied with or without DVH constraints. Deliverable plans were for comparative purposes generated without performing any projection. Minor differences between the studied delivery techniques are elaborated in Subsections 2.F.1–2.F.3.
F.4. DVH results for projections onto Pareto surface. Plans projected without DVH constraints are indicated by solid lines, plans projected with DVH constraints indicated by dashed lines, and plans generated without performing the projection indicated by dotted lines.

2.F.1. Step-and-shoot IMRT

The plans in the Pareto surface representation were generated by fluence map optimization with respect to dose calculated using a singular value decomposition (SVD) of pencil beam kernels, similar to Bortfeld et al.\textsuperscript{28} The navigated plan was made deliverable by an optimization where the error in DVH due to the conversion was minimized, see Bokrantz.\textsuperscript{19} This minimization was performed with leaf positions and segment weights as variables, see Hårdemark et al.,\textsuperscript{29} with the SVD dose augmented with intermediate and final dose calculations performed using a collapsed cone algorithm, see, e.g., Ahnesjö.\textsuperscript{30} The projection was performed using the same set of variables and dose calculation algorithms.

2.F.2. Sliding window IMRT

The calculation of the Pareto surface representation and the projection were both performed with fluence as variables.

The projected plan was converted to control points by sliding window conversion, see, e.g., Kamath.\textsuperscript{31} All dose distributions were calculated by SVD.

2.F.3. IMPT

The calculation of the Pareto surface representation and the projection were both performed with spot weights as variables. All dose distributions were calculated using a pencil beam algorithm.

2.G. Evaluation criteria

Plan quality was assessed with respect to a selection of dose–volume statistics. The dose to OARs was assessed in terms of dose-to-volume levels $V_x$ (the fractional volume of a structure that receives a dose greater than or equal to $x$ Gy), volume-to-dose levels $D_x$ (the minimum dose such that the
associated isodose volume contains \( x \% \) of the volume of a structure, and mean dose levels \( \bar{D} \). The planned dose to target structures was assessed in terms of a homogeneity index (HI) Ref. 32 according to

\[
HI = \frac{(D_2 - D_{95})}{D_{50}},
\]

and a conformity index (CI) Ref. 33 according to

\[
CI = \frac{V_{95\%}^{\text{External}}}{V_{95\%}^{\text{PTV}}},
\]

where \( V_{95\%} \) is the volume contained within the isodose volume defined at 95\% of the prescription level and \( V_{95\%}^{\text{PTV}} \) the total volume of all targets with prescription level greater than or equal to the prescription level of the structure to which the index refers.

### Table I. Dose statistics for the prostate case. Values where the projection resulted in a relative improvement of 5\% are indicated in bold.

<table>
<thead>
<tr>
<th>Plan</th>
<th>PTV(_{24}^{\text{HI}}) (%)</th>
<th>PTV(_{59.2}^{\text{HI}}) (%)</th>
<th>Bladder (D_{10}) (\text{Gy})</th>
<th>Rectum (D_{10}) (\text{Gy})</th>
</tr>
</thead>
<tbody>
<tr>
<td>No projection</td>
<td>8.2</td>
<td>117.6</td>
<td>27.9</td>
<td>111.1</td>
</tr>
<tr>
<td>ss-IMRT</td>
<td>Projected</td>
<td>8.9</td>
<td>115.7</td>
<td>27.6</td>
</tr>
<tr>
<td></td>
<td>No projection</td>
<td>8.4</td>
<td>116.1</td>
<td>27.7</td>
</tr>
<tr>
<td></td>
<td>Projected</td>
<td>9.2</td>
<td>117.0</td>
<td>27.3</td>
</tr>
<tr>
<td></td>
<td>No projection</td>
<td>7.8</td>
<td>116.3</td>
<td>27.1</td>
</tr>
<tr>
<td></td>
<td>Projected</td>
<td>8.6</td>
<td>114.1</td>
<td>27.0</td>
</tr>
<tr>
<td></td>
<td>No projection</td>
<td>7.5</td>
<td>115.3</td>
<td>26.4</td>
</tr>
<tr>
<td></td>
<td>Projected</td>
<td>8.4</td>
<td>115.1</td>
<td>26.8</td>
</tr>
<tr>
<td>IMPT</td>
<td>Projected</td>
<td>8.4</td>
<td>129.9</td>
<td>12.3</td>
</tr>
</tbody>
</table>

3. RESULTS

Our numerical results are summarized by the DVHs in Fig. 4 and the dose statistics in Tables I and II. Results are shown for plans subject to no projection, subject to a projection without DVH constraints, and subject to a projection under DVH constraints. Planning target volumes (PTVs) are designated by their prescription level in subscript.

The projection of a navigated plan onto the Pareto surface led to improved OAR sparing and better dose conformity for all three delivery techniques and both patient cases. The improved OAR sparing was most pronounced in the low and moderate dose regions, whereas the high-dose regions generally did not improve much, see, e.g., \( D_{10} \) for the bladder and rectum of the prostate case in Table I. The largest improvements in dose conformity occurred for low-dose targets, see, e.g., PTV\(_{59.2}\) of the IMPT plan for the prostate case and PTV\(_{50}\) and PTV\(_{60}\) of the ss-IMRT and IMPT plan for the head and neck case. The improvements in target homogeneity were very minor, except for PTV\(_{66}\) of the IMPT plan of the head and neck case.

A projection without DVH constraints only in rare instances led to a deterioration in some dose statistics. Such occurrences are the reduced homogeneity for PTV\(_{24}\) of the ss-IMRT and sw-IMRT plan for the prostate case, the increase of \( D_{10} \) for the rectum of the IMPT plan for the prostate case, and the decrease in homogeneity for PTV\(_{66}\) of the ss-IMRT plan for the head and neck case. These deteriorations did not occur when DVH constraints were used; however, the improvements were then smaller overall.

Table III further quantifies the main observed effect of the projections, namely, that the OAR sparing was improved but at a mild dose increase in the high-dose regions of OARs unless DVH constraints were used. The improved sparing of OARs is in the tabulated data quantified by two-sided DVH curve differences while violations of the navigated DVH are quantified by one-sided DVH curve differences. Clearly, a projection onto the Pareto surface poses a trade-off between

### Table II. Dose statistics for the head and neck case. Values where the projection resulted in a relative improvement of 5\% or more are indicated in bold.

<table>
<thead>
<tr>
<th>Plan</th>
<th>PTV(_{66}) (HI) (%)</th>
<th>PTV(_{66}) (CI) (%)</th>
<th>PTV(_{50}) (HI) (%)</th>
<th>PTV(_{50}) (CI) (%)</th>
<th>L Parotid (V_{30}) (\hat{D}) (\text{Gy})</th>
<th>R Parotid (V_{30}) (\hat{D}) (\text{Gy})</th>
</tr>
</thead>
<tbody>
<tr>
<td>No projection</td>
<td>6.8</td>
<td>132.4</td>
<td>12.0</td>
<td>160.1</td>
<td>18.6</td>
<td>152.7</td>
</tr>
<tr>
<td>ss-IMRT</td>
<td>Projected</td>
<td>6.6</td>
<td>127.4</td>
<td>11.3</td>
<td>147.8</td>
<td>18.8</td>
</tr>
<tr>
<td></td>
<td>No projection</td>
<td>6.3</td>
<td>127.2</td>
<td>11.6</td>
<td>151.7</td>
<td>18.5</td>
</tr>
<tr>
<td></td>
<td>Projected</td>
<td>6.8</td>
<td>124.3</td>
<td>10.4</td>
<td>145.0</td>
<td>19.3</td>
</tr>
<tr>
<td>sw-IMRT</td>
<td>Projected</td>
<td>6.8</td>
<td>124.1</td>
<td>10.1</td>
<td>141.9</td>
<td>18.8</td>
</tr>
<tr>
<td></td>
<td>No projection</td>
<td>6.9</td>
<td>123.5</td>
<td>10.0</td>
<td>141.8</td>
<td>19.1</td>
</tr>
<tr>
<td></td>
<td>Projected</td>
<td>8.2</td>
<td>126.8</td>
<td>11.2</td>
<td>127.5</td>
<td>16.9</td>
</tr>
<tr>
<td></td>
<td>No projection</td>
<td>8.4</td>
<td>129.9</td>
<td>12.3</td>
<td>128.5</td>
<td>16.8</td>
</tr>
</tbody>
</table>
the degree of plan improvement and the acceptable violation of the navigated DVH. The average decrease in dose to OARs and the average violation of the navigated DVH was 3.13 and 0.18 Gy, respectively. These figures should be contrasted to an average dose decrease for OARs at 1.98 Gy and a vanishing small violation of the navigated DVH for projection with DVH constraints.

4. DISCUSSION

Our results show that there exist situations when a projection onto the Pareto surface can improve OAR sparing and dose conformity of the navigated plan. This conclusion holds true both in the unconstrained case and if DVH constraints are used to preserve clinical goals. The DVH constraints were found effective for prevention of a dose increase in the high-dose region of OARs, but dampened the magnitude of the overall improvements. We, therefore, only recommend such constraints for structures where it is critical to maintain the navigated DVH exactly, e.g., if the dose to the structure just barely meets the clinical acceptance criteria. Another option is to first perform an unconstrained projection and then perform a second optimization that includes DVH constraints if necessary.

The observed dose improvements due to the projections were of the order of several Grays. This magnitude is, however, a function of the approximation error to Pareto optimality for the navigate plan, which depends on the number of objectives, the number of plans used to represent the Pareto surface, and how large dose variations that the set of constraints permit. Our study only covers a narrow spectrum of the possible values for these parameters: 8–10 objectives, 16–20 plans in the representations, and a single set of constraints per patient case. The results should therefore not be extrapolated to conclude that Pareto surface navigation yields plans that are suboptimal in terms of OAR sparing in general. Rather, we envisage that

5. CONCLUSIONS

We have presented a method that eliminates or reduces the error to Pareto optimality that arises during Pareto surface navigation. The error is removed through minimization of a projective distance to the ideal point in the objective function space. An augmented form of the projection was also suggested where the DVH distribution of the projected solution is required to be at least as good as that of the initial navigated plan. Empirical results with respect to two clinical cases and three delivery techniques show that the projections can lead to improved OAR sparing and better dose conformity at maintained, or slightly improved, target coverage. The main mechanism behind the improvements observed in this study was a reduction of the low to moderate dose to healthy structures.

ACKNOWLEDGMENTS

The authors thank Anders Forsgren and Björn Hårdemark for careful reading and constructive comments on earlier drafts. The second author’s work was carried out during a visiting professorship at the KTH Royal Institute of Technology.

Table III. Mean two-sided and one-sided differences along the dose axis between DVH curves of projected plans and corresponding plans generated without performing any projection.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Mean two-sided</th>
<th>Mean one-sided</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder</td>
<td>(Gy)</td>
<td>(Gy)</td>
</tr>
<tr>
<td>Rectum</td>
<td>(Gy)</td>
<td>(Gy)</td>
</tr>
<tr>
<td>L Parotid</td>
<td>(Gy)</td>
<td>(Gy)</td>
</tr>
<tr>
<td>R Parotid</td>
<td>(Gy)</td>
<td>(Gy)</td>
</tr>
</tbody>
</table>

Two-sided = \( \int_{0}^{1} D(v, d) - D(v, \bar{d}) \) \( dv \), one-sided = \( \int_{0}^{1} \max(D(v, d) - D(v, \bar{d})) \), \( dv \).
The optimization formulations that were used in the numerical experiments are summarized in Tables IV and V.

### APPENDIX: OPTIMIZATION PROBLEM FORMULATIONS

The optimization formulation for the prostate case. The reference dose level of a function is denoted \( \hat{d} \).

The constraints used during proton and photon therapy planning are indicated by “Pr” and “Ph” in subscript, respectively.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Function</th>
<th>( \hat{d} ) (Gy)</th>
<th>Structure</th>
<th>Function</th>
<th>( \hat{d}_{PH} ) (Gy)</th>
<th>( \hat{d}_{Pr} ) (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTV(_{74})</td>
<td>Min dose</td>
<td>74.00</td>
<td>PTV(_{74})</td>
<td>Min dose</td>
<td>66.60</td>
<td>68.00</td>
</tr>
<tr>
<td></td>
<td>Uniform dose</td>
<td>74.00</td>
<td></td>
<td>Min 95% DVH</td>
<td>71.78</td>
<td>72.52</td>
</tr>
<tr>
<td>PTV(_{59.2})</td>
<td>Min dose</td>
<td>59.20</td>
<td></td>
<td>Max dose</td>
<td>81.04</td>
<td>79.92</td>
</tr>
<tr>
<td>PTV(<em>{59.2}–PTV(</em>{74})</td>
<td>Uniform dose</td>
<td>59.20</td>
<td>PTV(_{59.2})</td>
<td>Min dose</td>
<td>53.28</td>
<td>53.28</td>
</tr>
<tr>
<td>Bladder</td>
<td>Max EUD ( a = 2 )</td>
<td>0.00</td>
<td></td>
<td>Min 95% DVH</td>
<td>56.24</td>
<td>56.24</td>
</tr>
<tr>
<td>Rectum</td>
<td>Max EUD ( a = 2 )</td>
<td>0.00</td>
<td>PTV(<em>{59.2}–PTV(</em>{74})</td>
<td>Max 5% DVH</td>
<td>66.50</td>
<td>65.71</td>
</tr>
<tr>
<td>PTV shell [5, 15] mm</td>
<td>Max EUD ( a = 2 )</td>
<td>0.00</td>
<td></td>
<td>Max dose</td>
<td>81.04</td>
<td>79.92</td>
</tr>
<tr>
<td>External</td>
<td>Dose falloff 2 cm</td>
<td>74.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The optimization formulation for the head and neck case. The reference dose level of a function is denoted \( \hat{d} \).

<table>
<thead>
<tr>
<th>Structure</th>
<th>Function</th>
<th>( \hat{d} ) (Gy)</th>
<th>Structure</th>
<th>Function</th>
<th>( \hat{d}_{PH} ) (Gy)</th>
<th>( \hat{d}_{Pr} ) (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTV(_{66})</td>
<td>Min dose</td>
<td>66.00</td>
<td>PTV(_{66})</td>
<td>Min dose</td>
<td>59.40</td>
<td>60.72</td>
</tr>
<tr>
<td></td>
<td>Uniform dose</td>
<td>66.00</td>
<td></td>
<td>Min 95% DVH</td>
<td>62.70</td>
<td>63.36</td>
</tr>
<tr>
<td>PTV(_{60})</td>
<td>Min dose</td>
<td>60.00</td>
<td></td>
<td>Max dose</td>
<td>72.60</td>
<td>72.60</td>
</tr>
<tr>
<td></td>
<td>Uniform dose</td>
<td>60.00</td>
<td>PTV(_{60})</td>
<td>Min dose</td>
<td>54.00</td>
<td>55.20</td>
</tr>
<tr>
<td>PTV(_{50})</td>
<td>Min dose</td>
<td>50.00</td>
<td></td>
<td>Min 95% DVH</td>
<td>57.00</td>
<td>57.60</td>
</tr>
<tr>
<td></td>
<td>Uniform dose</td>
<td>50.00</td>
<td>PTV(_{50})</td>
<td>Max 5% DVH</td>
<td>66.00</td>
<td>66.00</td>
</tr>
<tr>
<td>L Parotid</td>
<td>Max EUD ( a = 1 )</td>
<td>0.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R Parotid</td>
<td>Max EUD ( a = 1 )</td>
<td>0.00</td>
<td>PTV(_{50})</td>
<td>Min dose</td>
<td>45.00</td>
<td>45.00</td>
</tr>
<tr>
<td>PTV shell [5, 15] mm</td>
<td>Max EUD ( a = 2 )</td>
<td>0.00</td>
<td></td>
<td>Max 5% DVH</td>
<td>47.50</td>
<td>47.50</td>
</tr>
<tr>
<td>External</td>
<td>Dose falloff 2 cm</td>
<td>66.00</td>
<td></td>
<td>Max dose</td>
<td>57.50</td>
<td>55.00</td>
</tr>
<tr>
<td>Brainstem</td>
<td>Max dose</td>
<td>52.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal cord</td>
<td>Max dose</td>
<td>48.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>External</td>
<td>Max dose</td>
<td>72.60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

3) Electronic addresses: bokrantz@kth.se and rasmus.bokrantz@raysearchlabs.com.


24 Multi criteria optimization in RayStation, RaySearch Laboratories, white paper, 2012.
32 ICRU, “Prescribing, recording, and reporting photon beam intensity-modulated radiation therapy (IMRT),” ICRU Report 83 (International Commission on Radiation Units and Measurements, Bethesda, Maryland, 2010).